🔗 Share this article WHO Raises Concern Over Critical Scarcity of Obesity Jabs Fewer than a tenth of patients who could benefit from weight-loss injections including Wegovy are able to get them, states the global health agency as it publishes its initial recommendations on the therapies. Given over a billion people worldwide now classified as obese, it is calling for broader and more equitable access to these injectable treatments. Per estimates, more than two billion are projected to be living with obesity by 2030 unless action is taken. "The latest guidelines affirms that excess weight is a long-term condition that can be addressed with holistic and ongoing support," stated its chief Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and logistical bottlenecks are significant barriers to widespread access to the injections that can aid individuals in losing considerable body mass, notes the agency. GLP-1 Therapy Supply Crisis Despite the present best projected scenario, the manufacturing of these medications might only reach around 100 million people – fewer than 10% of those who need them, as stated by the WHO. The recommendation urges governments and firms to expand availability, through approaches including patent sharing. Exclusive production rights on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is due to expire in several nations in 2026. The Way Obesity Drugs Operate These medications mimick a biological compound to delay gastric emptying, reduce hunger and increase satiety so individuals eat less. Individuals commonly begin shedding pounds after several weeks of starting on the once-weekly jabs. Evidence suggests users may see weight return after a year of stopping the drug, as their usual appetite resume. To be carrying excess weight raises your likelihood for experiencing health problems, like diabetes, heart disease, stroke, and certain cancers. Excess weight impacts individuals in every country and was responsible for millions of fatalities worldwide in 2024, according to the WHO.
Fewer than a tenth of patients who could benefit from weight-loss injections including Wegovy are able to get them, states the global health agency as it publishes its initial recommendations on the therapies. Given over a billion people worldwide now classified as obese, it is calling for broader and more equitable access to these injectable treatments. Per estimates, more than two billion are projected to be living with obesity by 2030 unless action is taken. "The latest guidelines affirms that excess weight is a long-term condition that can be addressed with holistic and ongoing support," stated its chief Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and logistical bottlenecks are significant barriers to widespread access to the injections that can aid individuals in losing considerable body mass, notes the agency. GLP-1 Therapy Supply Crisis Despite the present best projected scenario, the manufacturing of these medications might only reach around 100 million people – fewer than 10% of those who need them, as stated by the WHO. The recommendation urges governments and firms to expand availability, through approaches including patent sharing. Exclusive production rights on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is due to expire in several nations in 2026. The Way Obesity Drugs Operate These medications mimick a biological compound to delay gastric emptying, reduce hunger and increase satiety so individuals eat less. Individuals commonly begin shedding pounds after several weeks of starting on the once-weekly jabs. Evidence suggests users may see weight return after a year of stopping the drug, as their usual appetite resume. To be carrying excess weight raises your likelihood for experiencing health problems, like diabetes, heart disease, stroke, and certain cancers. Excess weight impacts individuals in every country and was responsible for millions of fatalities worldwide in 2024, according to the WHO.